Buy Incyte (INCY) on Weakness - BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Incyte (INCY) IDO Patient Count Worries Are A "Nothing Burger" - Barclays
June 5, 2017 4:13 PM EDTBarclays maintains Overweight on Incyte (NASDAQ: INCY) price target of $180.00.
Analyst Dr. Geoff Meacham continues to holds INCY scientific and clinical leadership team in high regard and says it is very common to see different numbers of evaluable patients based upon exposure... More
